Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price rose 8.2% during mid-day trading on Monday . The company traded as high as $39.03 and last traded at $38.61. Approximately 174,823 shares were traded during trading, a decline of 71% from the average daily volume of 604,009 shares. The stock had previously closed at […]
Primecap Management Co. CA reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,052,648 shares of the company’s stock after selling 214,773 shares during the period. […]
BOSTON - Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases,.
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 Rhythm.